pharmaphorum October 15, 2024
Eli Lilly has said it is prepared to invest £279 million ($364 million) in the UK and work with the government to tackle serious public health challenges, including obesity.
The proposal, unveiled at the government’s International Investment Summit today is headlined by the creation of a UK biotech hub – provisionally called Lilly Gateway Labs (LGL) – to support early-stage life sciences businesses working on new medicine.
The LGL plan would garner funding of £204 million over three years, providing start-ups with Lilly’s expertise, access to lab space, and potentially financial investments, and would establish the first LGL site in Europe. Lilly already has LGLs in four locations in the US and said it is also considering a second in...
Today's Sponsors
Today's Sponsor